ClinicalTrials.gg
Active, not recruitingNCT06878365Updated Nov 13, 2026

A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies

A Phase 1 interventional study of BI 3000202_low dose and BI 3000202_high dose in Type 1 Interferonopathies, sponsored by Boehringer Ingelheim. Active, not recruiting at 20 sites in 9 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Updated Nov 13, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 74 Years
Sex
All
01

Study summary

This study is open to adults with selected type 1 interferonopathies. People can join the study if they have Aicardi-Goutières syndrome (AGS), Coatomer subunit alpha (COPA) syndrome, Familial chilblain lupus (FCL), or another type 1 interferonopathy with a specific gene mutation.

The purpose of this study is to find out how BI 3000202 is tolerated in people with selected type 1 interferonopathies. Participants take a lower dose of BI 3000202 as tablets for 4 weeks. Afterwards, they take a higher dose of BI 3000202 as tablets for 36 weeks. They may continue with the study treatment until every participant has completed 40 weeks of treatment (about 9 months). The participants may also continue their regular treatment for their condition during the study.

During this study, participants visit the study site 13 times or more, depending on when they start their participation. The doctors check the health of the participants and note any health problems that could have been caused by BI 3000202.

02

Conditions studied

  • Type 1 Interferonopathies
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female adult patients from ≥18 years (or alternative age for adults based on local regulations) to \<75 years.
  • Genetic diagnosis with mutations in the following affected genes: three prime repair exonuclease 1 (TREX1), ribonuclease H2 subunit A, B or C (RNASEH2B, RNASEH2C, RNASEH2A), SAM And HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1 (SAMHD1), U7 Small Nuclear RNA Associated sm-like protein (LSM11), RNA component of the U7 snRNP (RNU7-1) for AGS; Coatomer subunit alpha (COPA) for COPA syndrome; TREX1, SAM And HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1 (SAMHD1) for Familial chilblain lupus (FCL); DNA nuclease 2 (DNASE2), Adenosine triphosphate synthase family AAA domain containing 3A (ATAD3A) for other type 1 interferonopathies. Genotype documented in medical history is sufficient for eligibility determination and does not require confirmation. Variant identification as "pathogenic" or "likely pathogenic" is preferred according to a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. In the absence of such identification, clinical assessment of pathogenicity is required to be documented in the medical records.
  • Patients may be either:

    • On standard of care, provided it is on stable doses
    • Not on standard of care
  • If women of (WOCBP): must be ready and able to use highly effective methods of . Non-vasectomised male trial participants whose sexual partner is a woman of childbearing potential must be ready and able to use male contraception.

Exclusion criteria

Exclusion Criteria:

  • Major chronic inflammatory or connective tissue disease other than selected type 1 interferonopathies, as assessed by the investigator.
  • Increased risk of infectious complications based on investigator's judgement.
  • Evidence of potential moderate to severe loss of kidney function.
  • Evidence of hepatic impairment.
  • Further exclusion criteria apply.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    BI 3000202

    Drug: BI 3000202_low dose · Drug: BI 3000202_high dose

Interventions

  • DrugBI 3000202_low dose

    BI 3000202\_low dose

  • DrugBI 3000202_high dose

    BI 3000202\_high dose

06

What researchers measure

Primary outcomes

  1. Occurrence of any treatment-emergent adverse events assessed as related to study drug

    Time frame: Approximately 72 weeks

Secondary outcomes

  1. Area under the concentration-time curve of BI 3000202 in plasma from time 0 to 4 hours after administration of the first dose ( AUC0-4)

    Time frame: At Day 1

  2. Maximum measured concentration of BI 3000202 in plasma after administration of the first dose (Cmax)

    Time frame: At Day 1

  3. Area under the concentration-time curve of BI 3000202 in plasma from time 0 to 4 hours at steady state (AUC0-4,ss)

    Time frame: At Days 29 and 85

  4. Maximum measured concentration of BI 3000202 in plasma at steady state (Cmax,ss)

    Time frame: At Days 29 and 85

  5. Predose concentration of BI 3000202 in plasma at steady state immediately before administration of the next dose (Cpre,ss)

    Time frame: At Days 29 and 85

  6. Change from baseline in interferon gene score (IGS)

    Time frame: At baseline, at Week 12

07

Study locations

20 sites
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After structured results have been posted, all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2025 (actual). Primary completion is estimated for Dec 2029, 52 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Dec 2026 → Dec 2029 and completion Dec 2026 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2025
First posted
Mar 17, 2025
StartActual
Jul 29, 2025
Primary completionEst.
Dec 10, 2029was Dec 2026
CompletionEst.
Dec 20, 2029was Dec 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (1 Portugal, 1 Spain)
  • ULS de Santa Maria, E.P.E - Hospital de Santa Maria · Lisbon, Portugal
  • Hospital Universitario Virgen del Rocio · Seville, Spain
Show 2 removed
  • ULS de Santa Maria, E.P.E · Lisbon, Portugal
  • Hospital Virgen del Rocio · Seville, Spain
Nov 13, 2026
Primary completion
Dec 6, 2026→Dec 10, 2029
Nov 13, 2026
Study completion
Dec 7, 2026→Dec 20, 2029
Nov 13, 2026
Show all 2 updates
  1. Nov 13, 2026
    2 sites added, 2 sites removed
    Show 2 added (1 Portugal, 1 Spain)
    • ULS de Santa Maria, E.P.E - Hospital de Santa Maria · Lisbon, Portugal
    • Hospital Universitario Virgen del Rocio · Seville, Spain
    Show 2 removed
    • ULS de Santa Maria, E.P.E · Lisbon, Portugal
    • Hospital Virgen del Rocio · Seville, Spain
    Primary completion Dec 6, 2026→Dec 10, 2029
    Study completion Dec 7, 2026→Dec 20, 2029
    + 1 other change: verification date
  2. Oct 14, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06878365
Responsible party
Sponsor
First posted
Mar 17, 2025
Start date
Jul 29, 2025
Primary completion
Dec 10, 2029 (estimated)
Completion
Dec 20, 2029 (estimated)
Last update
Nov 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion